Skip to main content
Premium Trial:

Request an Annual Quote

BlueGnome Opens US 'Logistics Hub' to Serve North American Customers


BlueGnome recently announced the operational launch its American subsidiary, BlueGnome Inc., in Fairfax, Va., outside of Washington, DC.

Graham Snudden, the BlueGnome's vice president of engineering, told BioArray News in an e-mail that the company now has six employees in the US: two on the West Coast and four working out of the new office.

BlueGnome, based in Cambridge, UK, sells microarrays and other products for screening chromosomal abnormalities in cytogenetics and pre-implantation genetics. The company has expanded in the past year, doubling its headcount to about 50 employees, moving into a larger headquarters, and establishing a sales office in Singapore (BAN 3/13/2012).

BlueGnome's new North American location will include a logistics facility to invoice and fulfill orders for the company's customers. CEO Nick Haan said in a statement that having a "logistics hub" close to Washington Dulles International Airport provides BlueGnome's North American clients with a "short supply chain" and access to customer service.

Some of BlueGnome's customers in the US include Southern California's Pacific Reproductive Center and the Fairfax, Va.-based Genetics and IVF Institute, fertility practices that use BlueGnome's comparative genomic hybridization arrays in pre-implanation screening as part of in vitro fertilization cycles.

One customer, Elena Kolomietz, who is co-head of the division of diagnostic molecular genetics at Mount Sinai Hospital in Toronto, said in a statement that maintaining a secure supply of BlueGnome arrays is "increasingly important" as the hospital expands its use of microarrays into a growing number of applications. Kolomietz "welcomed" BlueGnome's ability to provide technical support and fulfilment of orders "from within our time zone."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.